Cassava Sciences Aktie
WKN DE: A2PGL8 / ISIN: US14817C1071
|
22.07.2024 17:27:33
|
Why Cassava Sciences Stock Is Skyrocketing Today
Shares of Cassava Sciences (NASDAQ: SAVA) were skyrocketing 29.6% higher as of 10:53 a.m. ET on Monday. The big gain came after executive chairman Rick Barry released an open letter to shareholders, employees, principal investigators, and patients.Barry was appointed as Cassava's executive chairman on July 17, 2024. He has served on the biopharmaceutical company's board of directors since June 2021. Barry is leading Cassava as it searches for a new CEO following former CEO Remi Barbier's resignation last week. Perhaps more than anything, investors liked Barry's optimistic yet candid tone in his open letter. He acknowledged skepticism about the company but emphasized Cassava's positive phase 2 results for its experimental Alzheimer's disease drug simufilam.Continue readingWeiter zum vollständigen Artikel bei MotleyFool
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Cassava Sciencesmehr Nachrichten
| Keine Nachrichten verfügbar. |
Analysen zu Cassava Sciencesmehr Analysen
Aktien in diesem Artikel
| Cassava Sciences | 1,11 | -5,45% |
|
Letzte Top-Ranking Nachrichten
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.